Several possible studies
Story checked
FDA Approves Tudriqev for Advanced Skin Cancer (opens in a new tab)
webmd.com · 2026-08-10
Short answer
Several possible studiesNo clear answer.
More than one paper fits the article's details, and none fits well enough to single out. Checking claims against the wrong study would be worse than not checking them at all.
Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.
Share this check
The story
FDA Approves Tudriqev for Advanced Skin Cancer
webmd.com · 2026-08-10
The story’s checkable claims.
Read the original story (opens in a new tab)NewsLink checks it
Several studies could be the source of this story.
More than one paper fits the article's details, and none fits well enough to single out. Checking claims against the wrong study would be worse than not checking them at all.
Open claim evidenceSearch result
Several studies could fit.
More than one paper fits the article's details, and none fits well enough to single out. Checking claims against the wrong study would be worse than not checking them at all.
Evidence layer
Claim by claim
What the story asserts. With no source study, there is nothing to check these against.
Reading mode
Scan verdicts. Open evidence only when needed.
Claim 1 of 4Not checkedThe FDA has approved Tudriqev (vusolimogene oderparepvec-wtpg) to treat adults with advanced cutaneous melanoma that cannot be removed by surgery and has gotten worse after treatment with certain immune-boosting medicines.View evidenceHide evidence
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 2 of 4Not checkedTudriqev is used together with another cancer medicine called nivolumab, and it is described as a modified herpes-virus treatment designed to target and kill cancer cells.View evidenceHide evidence
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 3 of 4Not checkedThe FDA approval was based on a clinical trial with 140 adults; in the main treated group of 91 patients, about 24% saw their tumors shrink or disappear, and the median duration of response was 14.1 months.View evidenceHide evidence
As statedabout 24% response; median response duration 14.1 months
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 4 of 4Not checkedThe approval was granted under an accelerated program based on tumor response rates, and an ongoing study will check whether the benefits hold up over longer follow-up.View evidenceHide evidence
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Method layer
No single source study was found.
NewsLink still surfaces nearby research so you can inspect the field instead of a single paper.
Nearby research
No exact source, but these papers are close.
PubMed, Crossref, Europe PMC · 15 candidate papers
Vusolimogene oderparepvec (Tudriqev) - an oncolytic viral therapy for melanoma.
The Medical Letter on Drugs and Therapeutics · 2026 · PubMed, Crossref
Biodistribution, shedding, and transmissibility of vusolimogene oderparepvec (RP1).
Frontiers in Oncology · 2026 · PubMed, Europe PMC
Dacarbazine and interferon-?? 2a in advanced malignant melanoma
Melanoma Research · 1995 · Crossref
Updates on intratumoral therapies in melanoma
2026 · Europe PMC
Melanoma vaccines: current R&D landscape, translational hurdles, and future outlook-a perspective drawn from 442 clinical trials.
Frontiers in Immunology · 2025 · PubMed
And 10 more candidates considered.